ArticleMolecular cancer therapeutics2015

Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Valerie N Barton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.